Subscribe
www-billionphotos-com-shutterstock-com-11
www.BillionPhotos.com / Shutterstock.com
29 February 2016Americas

Polymer patent invalidated by split Federal Circuit

The US Court of Appeals for the Federal Circuit has invalidated a polymer patent owned by Howmedica Osteonics, reversing an earlier decision from the US Patent and Trademark Office (USPTO) and ending the company’s long running dispute with medical device company Zimmer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit upholds Howmedica patent ruling
13 May 2016   The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Federal Circuit upholds Howmedica patent ruling
13 May 2016   The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.

More on this story

Americas
Federal Circuit upholds Howmedica patent ruling
13 May 2016   The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims